IXICO plc Exercise of share options (3456C)
April 12 2017 - 7:41AM
UK Regulatory
TIDMIXI
RNS Number : 3456C
IXICO plc
12 April 2017
The following amendments have been made to the ' Exercise of
share options' announcement released on 29 March 2017 at 15.30
under RNS No 9236A.
The date of admission of the New Ordinary Shares is 20 April
2017.
All other details remain unchanged.
The full amended text is shown below.
12 April 2017
IXICO plc
("IXICO" or the "Company")
Exercise of share options
IXICO, the brain health company, announces that Dr Janet Munro
and Mr Ken Tubman have exercised options granted to them by Optimal
Medicine Limited. In accordance with the terms of the Share
Purchase Agreement between the Company and Optimal Medicine Limited
on 18 November 2015 ('the Agreement') the new shares issued and
allotted in Optimal Medicine Limited are subject to a put and call
arrangement resulting in the Company issuing and allotting 55,846
new ordinary shares of 1 pence each in IXICO plc (the "New Ordinary
Shares")
Application has been made for the New Ordinary Shares to be
admitted to AIM on 20 April 2017. Upon admission of the New
Ordinary Shares to AIM, the enlarged issued share capital of the
Company will be 27,119,130 ordinary shares.
The Company does not hold any shares in treasury. Consequently,
27,119,130 is the figure which may be used by shareholders as the
denominator for the calculation by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company under the FCA's Disclosure and
Transparency Rules.
For further information please contact:
IXICO plc Tel: +44 20
Giulio Cerroni, Chief Executive 3763 7499
Officer
Susan Lowther, Chief Financial Officer
Shore Capital (Nomad and Broker) Tel: +44 20
Bidhi Bhoma / Edward Mansfield 7408 4090
FTI Consulting Limited (Investor Tel: +44 20
Relations) 3727 1000
Simon Conway/Mo Noonan/Matthew Moss
About IXICO
IXICO's innovative and proprietary digital healthcare
technologies help those involved in researching and treating
serious diseases to capture and analyse clinical data to make
rapid, informed decisions. In clinical research this includes the
phenotyping of patients, quantification of disease pathology and
measurement of patient outcomes. In clinical practice the mobile
health and digital decision support technologies aid diagnosis,
patient engagement and monitoring. IXICO is also collaborating with
partners to develop companion digital health products targeted at
improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease,
Huntington's disease, multiple sclerosis, Parkinson's disease,
behavioural health, child and adolescent mental health.
More information is available on www.ixico.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLLFFLSTIFLID
(END) Dow Jones Newswires
April 12, 2017 07:41 ET (11:41 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024